OncoSec's IL-12 construct shows positive effect in preclinical testing; shares ahead 8% premarket

|About: OncoSec Medical Incorp... (ONCS)|By:, SA News Editor

Nano cap OncoSec Medical (NASDAQ:ONCS) perks up 8% premarket on light volume in response to its announcement of positive preclinical data on its interleukin-12 (IL-12) construct. In a mouse model of melanoma, the company demonstrated that the changes it made to the plasmid design and electroporation parameters significantly increased IL-12 production leading to an anti-tumor effect. It says the new construct will be the backbone of its next-generation combination molecules.

The data are being presented today at the American Association of Cancer Research Annual Meeting in Washington, DC.